ResMed (MEX:RMD) Beta: -1.2363 (As of Jun. 24, 2026)


MEX:RMD ResMed Inc MEX:RMD
99 GF Score
Price MXN3,716.10
GF Value MXN5,298.64
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed Beta?

ResMed MEX:RMD 99 Beta is -1.2363 as of Jun. 24, 2026. GuruFocus rates MEX:RMD with a GF Score™ of 99/100 and a GF Value™ of MXN5,298.64 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), ResMed's Beta is -1.2363.


ResMed  (MEX:RMD) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


ResMed Beta Related Terms


ResMed Beta Historical Data

* Premium members only.

The historical data trend for ResMed's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Beta Chart

ResMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.23 -0.19 -0.49

ResMed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.39 -0.49 -0.56 -0.83 -1.06

MEX:RMD vs MDLN, WST, BDX: Beta Comparison

For the Medical Instruments & Supplies subindustry, ResMed's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Beta distribution charts can be found below:

* The bar in red indicates where ResMed's Beta falls into.


MEX:RMD
99GF Score
ResMed Inc MEX:RMD
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -1.2363 mean?
ResMed (MEX:RMD) has a Beta of -1.2363 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for ResMed and its competitors.
Is ResMed's Beta too high?
ResMed's current Beta is -1.2363. Overall, ResMed has a GF Score™ of 99/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Beta compare to MDLN and WST?
ResMed's Beta of -1.2363 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for ResMed and its competitors. ResMed's current Beta is -1.2363. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN5,298.64, compared to a current price of MXN3,716.10 — trading 29.9% below its estimated fair value. The current Beta is -1.2363. ResMed's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For ResMed (MEX:RMD), the current Beta is -1.2363 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (MEX:RMD) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of MXN3,716.10 is trading 29.9% below its estimated GF Value™ of MXN5,298.64. GuruFocus considers ResMed to be Significantly Undervalued.

Key valuation signals for MEX:RMD:

  • Beta: -1.2363
  • GF Value™: MXN5,298.64 vs. price of MXN3,716.10 (29.9% below fair value)
  • GF Score™: 99/100 with 1 warning sign

No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
99GF Score

Get the complete analysis for MEX:RMD

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,716.10
Price
MXN5,298.64
GF Value